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Summary The renal function was evaluated with '3'I-Hippuran clearance in 171 patients with malignant germ
cell tumours. Assessments were performed before treatment and at three fixed times afterwards within 5 years.
The patients were treated with surgery only (20 patients), infra-diaphragmatic radiotherapy only (median
midplane dose 36 Gy) (48 patients), cisplatin-based chemotherapy (total cisplatin dose 500-850 mg) plus
surgery (64 patients), cisplatin-based chemotherapy (total cisplatin dose> 850 mg) with or without surgery (23
patients) or cisplatin-based chemotherapy (total cisplatin dose 500-850mg) plus infra-diaphragmatic radio-
therapy (16 patients). No renal impairment was observed for patients treated with surgery only. In patients
who received radiotherapy no change of the renal function occurred during the first year post-treatment. Three
to five years after treatment discontinuation a statistically significant reduction within the normal range was
observed in patients who were >40 years at the time of irradiation. Cisplatin-based chemotherapy led to a
statistically significant irreversible renal impairment for all the three groups. The greatest reduction was seen in
patients who received the highest total cisplatin dose or who were treated with irradiation in addition to
chemotherapy. The clinical significance of the observed nephrotoxicity is still unknown.
There is a lack of comparative studies regarding nephrotoxi-
city after different treatment modalities for testicular cancer.
Renal toxicity is a well-known side effect after cisplatin-based
combination chemotherapy (Dentino et al., 1978; Offerman
et al., 1984; Safirstein et al., 1986), but less attention has been
paid to the possible renal impairment after high-voltage
abdominal radiotherapy and the combination of chemo-
therapy and irradiation.
The aim of the present prospective study was to evaluate
the renal function after retroperitoneal lymph node dissec-
tion, cisplatin-based chemotherapy, abdominal radiotherapy,
and after combined treatment with chemotherapy and irradi-
ation. Both the acute and the long-term results were assessed.
Patients and methods
A total of 171 patients with malignant germ cell tumours
(testicular 162, extragonadal nine) were included in the study
(Table I). These patients represented a consecutive series of
patients treated at The Norwegian Radium Hospital during
two periods (January 1983 to December 1984 and July 1985
to October 1986). Staging was performed according to the
Royal Marsden Staging System (Peckham et al., 1979). The
principles of primary treatment were as follows.
Seminoma
Clinical stage I, IIa/b: infra-diaphragmatic radiotherapy
36-40Gy (Fossa et al., 1989).
Clinical stage >Ilc/extragonadal germ cell tumours: cis-
platin-based combination chemotherapy (CVB: cisplatin
20mgm-2 days 1-5, vinblastine 0.10-0.15mgkg-' day
1-2, bleomycin 30 mg days 2, 5, 15 (max. cumulative dose
300 mg)) followed by radiotherapy/surgery to initial tumour-
bearing regions (Fossa et al., 1987). From 1983 vinblastine
was gradually replaced by VP-16 (500 mg m 2 per cycle)
(Aass et al., 1989).
Non-seminoma
Clinical stage I, Ila: retroperitoneal lymph node dissection
(RLND) followed by three or four cycles of cisplatin-based
chemotherapy in case of metastases (Fossa et al., 1990).
Clinical stage hIIb: cisplatin-based chemotherapy follow-
ed by surgery of residual masses within initial tumour-
bearing areas (Aass et al., 1990a). High-risk patients, as
defined previously (Aass et al., 1990a), were treated with a
so-called high-dose cisplatin regimen (BEP60: cisplatin 60 mg
m-2 days 1-3, VP-16 120mgm-2 days 1-3, bleomycin
30mg days 1, 5, 15 (max. cumulative dose 300mg)).
Procedure
The patients were divided into five different groups with
regard to their overall treatment (Table II). Group 1: uni-
lateral retroperitoneal lymph node dissection (RLND) (20
patients). Group 2: infra-diaphragmatic radiotherapy (48
patients). Group 3: cisplatin-based combination chemother-
apy (total cisplatin dose 500-850 mg) + RLND (64 patients).
Group 4: cisplatin-based combination chemotherapy (total
cisplatin dose >850mg) ± RLND (23 patients). Group 5:
cisplatin-based combination chemotherapy (total cisplatin
dose 500-850 mg) + infra-diaphragmatic radiotherapy (16
patients).
The series includes ten patients treated for relapse by
salvage chemotherapy. All patients in group 4 received at
least one cycle with high-dose cisplatin chemotherapy (one
cycle to one patient; two cycles to four patients; three cycles
to nine patients; four cycles to nine patients). The other
chemotherapy courses for this group and all courses for
groups 3 and 5 were given with conventional cisplatin doses,
i.e. 100 mg cisplatin m-2 per cycle. The total number of
chemotherapy cycles for patients in groups 3-5 were between
three and eight cycles (most often four cycles).
Radiotherapy was given with linear accelerators (5-6 MV).
Two opposed fields were given, one anterior and one pos-
terior. The daily dose was 2 Gy (five fractions per week). One
field was treated each day. Patients with stage I disease
received a total dose of 36 Gy, whereas patients with meta-
static disease received 40 Gy.
All patients in group 2 received treatment to a so-called
L-field including the paraaortic and iliac regions. Patients in
group 5 received either L-field irradiation or paraaortic
radiotherapy. If more than one third of the renal tissue was
included in the target volume, renal shielding was performed
after 20 Gy.
Three patients had suffered from urolithiasis before treat-
ment for the testicular cancer. In one of these patients partial
nephrectomy had been performed. As all these three patients
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Table I Patient characteristics
Group I Group 2 Group 3 Group 4 Group 5 Total
No. of patients 20 48 64 23 16 171
Testicular cancer 20 48 63 15 16 162
Initial stage
I 20 44 4 0 2 70
II 0 4 43 2 12 61
III 0 0 3 1 2 6
IV 0 0 13 12 0 25
Initial abdominal status
0 20 44 6 1 2 73
A 0 3 14 0 0 17
B 0 1 33 1 6 41
C 0 0 8 10 6 24
D 0 0 2 3 2 7
Extragonadal germ cell 0 0 1 8 0 9
tumour
Histology
Seminoma 0 47 4 0 16 67
Non-seminoma 20 1 60 23 0 104
Age at first evaluation
(years)
Median 28.3 35.5 26.8 24.1 37.6 29.5
Range 16.5-64.5 19.2-71.9 16.8-56.2 14.5-54.0 29.1-53.4 14.5-71.9
Table II Treatment characteristics
Group I Group 2 Group 3 Group 4 Group 5
RLNDI (no. of patients) 20 0 64 15 0
Nephrectomy (no. of patients) 0 0 1 4 0
Infra-diaphragmatic radiotherapy,
midplane dose (Gy)
Median 0 36 0 0 40
Range 32-40 36-40
Accumulated cisplatin dose (mg)
Median 0 0 743 1280 775
Range 515-840 870- 1750 560-820
Chemotherapy intensity
(mg month-I)b
Median 0 0 263 355 247
Range 221 -293 210-467 193-293
aRetroperitoneal lymph node dissection. bAccumulated cisplatin dose/duration of chemotherapy
treatment.
had normal '3'I-Hippuran clearance before therapy, they
were included in their respective groups.
The renal function was evaluated by determination of
'3'I-Hippuran clearance. From 1983 until 1986 the '3'I-
Hippuran clearance was measured according to Pixberg and
Just (1971) and since 1986 according to Oberhausen (1977).
A comparison between these two methods has previously
been done at our hospital and a correlation coefficient of 0.95
was found. The values of '311-Hippuran clearance are given as
percentages of the normal mean related to age, sex and body
surface of the patients (lower limit of normal mean 70%).
As a rule the first evaluation of renal function for all
patients was done after orchiectomy and before the start of
any additional treatment (Table III). The second assessment
of renal function in patients treated with surgery or radio-
therapy only was performed 2-3 months after therapy.
Patients who received chemotherapy with or without surgery
were evaluated for the second time about 4 weeks after the
start of the last chemotherapy cycle. For patients treated
with both chemotherapy and irradiation no evaluation
immediately after treatment discontinuation was performed.
Patients from all the five groups were reevaluated 1 year and
3-5 years (median 3.3 years, range 2.9-5.7 years) post-
treatment. The number of patients evaluated at different
times varies as not all patients had all three post-treatment
assessments.
Statistics
The PC based statistical program Medlog was used to calcu-
late means, medians and ranges and to compare distributions
with each other (Wilcoxon test). A P value of less than 0.05
was regarded as statistically significant
Table III Times of evaluation
4 weeks after
start oflast 2-3 months I year 3-5 years
Before chemotherapy after after after
treatment cycle treatment treatment treatment
Group I x x x x
Group 2 x x x x
Group 3 x x x x
Group 4 x x x x
Group 5 x x x844 N. AASS et al.
Results
For the patients treated with surgery only the renal function
remained unchanged after the operation and during the
whole follow-up period (Figure 1). After infra-diaphragmatic
radiotherapy no change in the renal function occurred during
the first year. With 3-5 years post-treatment observation
time a statistically significant reduction was seen for patients
older than 40 years at the time of treatment (P<0.03),
although the median value was still within the normal range
(Figure 2). At the last evaluation no renal impairment was
noted for patients who were 40 years or younger when they
received irradiation.
For patients from groups 3 and 4 cisplatin-based chemo-
therapy led to a statistically significant reduction of '3'I-
Hippuran clearance evaluated 4 weeks after start of the third
to fifth chemotherapy cycle compared to the pre-treatment
values (9% and 32% for groups 3 and 4, respectively)
(P<0.001). One year post-treatment the median reduction
was 8% for group 3, 35% for group 4 and 20% for group 5
(P<0.01). The renal impairment remained stable for all the
three groups 3-5 years after treatment discontinuation. No
difference was observed for patients who were 40 years or
younger at the time of treatment compared to those older
than 40 years. Although conventional cisplatin-based chemo-
therapy led to a significant reduction of the renal function,
the median post-treatment values were all within the normal
range for group 3. The median values after treatment discon-
tinuation for groups 4 and 5 were, however, below the
normal range at all times of evaluation.
Although no significant long-term renal function impair-
ment was seen in the majority of patients, particularly low
'1'I-Hippuran clearance values (< 50% ofnormal mean) were
observed 3-5 years after treatment in individual patients
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Figure 2 '3'I-Hippuran clearance in patients treated with infra-
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even after 'conventional' therapy. Such low values were
measured in one patient after radiotherapy, in two patients
after conventional cisplatin chemotherapy and in two
patients who received high-dose chemotherapy. All patients
treated with both chemotherapy and irradiation had values
>50%.
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Figure 1 '3II-Hippuran clearance related to different treatment
modalities for malignant germ cell tumours.
Discussion
The method to measure '3'I-Hippuran clearance at our hospi-
tal was changed in 1986. Thus, two different methods have
been applied during the years this study was conducted. In
clinical studies lasting for such a long time period this is not
unusual. Because of the good correlation between the two
methods (correlation coefficient 0.95) the change has prob-
ably not influenced our results to any great extent.
According to the first reports concerning the nephrotoxic
effects of cisplatin, the drug primarily causes tubular damage
(Gonzalez-Vitale et al., 1977). '3'I-Hippuran clearance with
glomerular and tubular secretion was thus chosen at our
hospital as the best method to discover the expected tubular
dysfunction. Methods recording only glomerular filtration
were thought to be less sensitive. Later reports have shown
that investigations measuring glomerular filtration only are
also of value for evaluation of the renal impairment caused
by cisplatin (Daugaard & Abildgaard, 1989).
No change of the median value of '3'I-Hippuran clearance
was observed at any time of evaluation for the patients
treated with surgery only. This is as expected, as RLND only
accidentally leads to renal complications (Whitmore, 1979;
Donohue & Rowland, 1981). In individual patients, however,
fluctuations of the renal function were observed. These were
not stable during the follow-up period, and represented
improvement as well as deterioration compared to pre-treat-
ment values. The measured fluctuations could not be cor-
related to changes in haematocrit. Some of the patients
developed vaso-vagal reactions during blood sampling.
Hypotension leads to reduced renal clearance, and this could
possibly in part explain the individual fluctuations.
The nephrotoxic effect of abdominal radiotherapy is well-
known. Older studies reported nephrotoxicity in testicular
cancer patients when orthovoltage irradiation and large fields
were used (Kunkler et al., 1952; Luxton, 1961). After the
introduction of modern radiotherapy techniques and reduc-
tion of the field size nephrotoxicity has not been a clinical
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problem for these patients (Duncan & Munro, 1987; Moul et
al., 1989), and subclinical nephrotoxicity has not been
studied using sensitive techniques.
Several studies have shown pathological renal scans with
reduced up-take of the isotope in the part of the kidney
included in the radiation field (Le Bourgeois et al., 1979;
Birkhead et al., 1979; Kim et al., 1984). There is, however, a
lack of dynamic studies evaluating a possible renal injury.
Avioli et al. (1963) assessed the acute effect of radiotherapy
on the renal function in ten patients. They found that the
most significant effect was on the renal plasma flow which
fell progressively during the treatment period beginning at
4 Gy. The renal plasma flow was still reduced 1-12 months
post-treatment, and during this time period it deteriorated
further in some patients. Also glomerular filtration rate
(GFR) was reduced at dose levels of 20-24 Gy. In Kim et
al.'s study (1984) nine of 18 lyphoma patients with normal
pre-treatment evaluation developed pathological renal scans
after discontinuation of abdominal radiotherapy. Seven of
the nine patients also had pathological '3'I-radiohippurate
perfusion studies. Unfortunately the patients were not eval-
uated at fixed points of time, but the reduced blood flow was
observed 7-85 months post-treatment. In two patients some
recovery of the perfusion function was demonstrated during
the follow-up period, whereas in three patients it was further
reduced. Moderate hypertension was diagnosed in one
patient post-treatment. Apart from this none of the patients
developed clinically overt symptoms or signs related to
nephropathy. Contrary to Avioli et al. and Kim et al. no
impairment of the renal function was observed the first year
post-treatment in the present study as evaluated by the
median values. In addition, 3 to 5 years after treatment
discontinuation a statistically significant reduction was
revealed among the patients older than 40 years at the time
of treatment, but not among the younger patients. Physio-
logically the renal function is reduced with increasing age.
Patients older than 40 years probably do not have the same
reserve capacity to compensate for the radiotherapy induced
nephrotoxicity as the younger patients. This is expressed as a
decrease of the Hippuran clearance in the former ones.
Today there is a general agreement that a midplane dose of
30 Gy is sufficient to treat stage I seminoma. It remains to be
shown whether this age-dependent renal function impairment
is also evident when using lower doses.
Many studies have been conducted to evaluate the renal
function after cisplatin-based chemotherapy using radio-
isotope techniques (Meijer et al., 1983; Fjeldborg et al., 1986;
Groth et al., 1986; Hansen et al., 1988; Macleod et al., 1988;
Hamilton et al., 1989). The majority of these studies assessed
GFR whereas we have evaluated effective renal plasma flow
(ERPF). In only one study of testicular cancer patients the
two parameters have been correlated (Meijer et al., 1983). In
this report a 12% and 26% reduction of GFR and ERPF,
respectively, was found. As only eight patients were included
in this comparative study it remains unknown whether GFR
or ERPF best describes the cisplatin induced nephrotoxicity.
In the present study a 9% reduction of the renal function
was found 4 weeks after start of the last chemotherapy cycle
when conventional cisplatin doses had been given. This im-
pairment remained stable during the following 3-5 years. In
other studies, which all evaluated GFR (Fjeldborg et al.,
1986; Groth et al., 1986; Hansen et al., 1988; Macleod et al.,
1988; Hamilton et al., 1989), a greater reduction (12-29%)
was found 12 months or later after treatment discontinua-
tion. The reason for the increased nephrotoxicity demonstrat-
ed in these studies as compared to our results is uncertain,
but could perhaps partly be related to different methods.
Some of the difference could also be due to the fact that no
age adjustment of the results were done in the other studies
as done by us. The renal impairment observed in the other
studies could, however, not be correlated to the accumulated
cisplatin dose.
Retroperitoneal metastases may obstruct the outflow from
the kidneys and may lead to decreased renal function. If the
obstruction has not lasted for too long, the renal function in
these patients usually improve during or after treatment. In
our study all patients were included irrespective of the pre-
treatment value of '1'I-Hippuran clearance. Seven of 64
patients treated with conventional cisplatin doses had a pre-
treatment value below the normal range. During the follow-up
period their values either improved or remained unchanged
resulting in an increase of the overall results. In the other
studies only patients with normal pre-treatment values or
only one to two patients with pathological pre-treatment
values were included. This different patient selection repre-
sents probably another explanation of our somewhat smaller
post-treatment reduction of the renal function than found in
other studies.
We did not find any improvement of the median value of
'3'I-Hippuran clearance during the follow-up period for
patients treated with conventional cisplatin doses. The results
from other studies are somewhat contradictory. Groth et al.
(1986) found that the renal function deteriorated during the
first year post-treatment, whereas Meijer et al. (1983) found a
slight improvement during the same time period. In Hansen
et al.'s study (1988) where the renal function was assessed 4
to 8 years post-treatment GFR normalised in 10/34 patients
and improved in 8/34 patients. No change of GFR was
found in Macleod et al.'s study (1988) (mean observation
time post-treatment 29 months) or in Hamilton et al.'s study
(1989) (median observation time post-treatment 30 months).
However, in all studies apart from Hansen et al.'s, the renal
function assessed at the latest time of evaluation was
significantly reduced compared to the pre-treatment values as
evaluated by the median or mean values.
The nephrotoxic effect of high-dose cisplatin chemotherapy
is greater than when conventional cisplatin doses is used, as
demonstrated in the present study, and in the study of
Daugaard et al. (1988). Our study also reveals a greater renal
impairment when conventional cisplatin chemotherapy is
combined with abdominal irradiation as compared to similar
chemotherapy given as the only cytotoxic treatment. Cis-
platin is known to have radiosensibilising effect (Douple,
1985), and in animal experiments increased nephrotoxicity
has been found after combined treatment compared to single
modality treatment (Stewart et al., 1986; Robbins et al.,
1988). To our knowledge no previous study in man has
evaluated this aspect. The results from the present series and
from another study conducted at our hospital to evaluate the
long-term somatic toxicity in testicular cancer patients both
demonstrate increased long-term toxicity after combined
treatment (Aass et al., 1990b).
So far we do not know the clinical significance of the renal
impairment demonstrated with radio-isotope techniques.
Theoretically the nephrotoxicity might cause increased inci-
dence of cardiovascular problems. In the study of Hansen et
al. (1988) blood pressure was measured before treatment and
at the latest follow-up examination. They found that six of
34 patients with normal pre-treatment values developed
hypertension after therapy. Based on the information in the
patients' records only three patients in the present series
developed cardiovascular disease during a follow-up period
of 3-5 years. As we did not ask the patients specifically
about symptoms of cardiovascular disease or objectively
evaluated it, we may have underestimated the extent of this
problem. In addition, much longer follow-up of the patients
will be necessary to assess the real risk of cardiovascular
disease. The changes of the renal function shown in the
present study may become of clinical importance in patients
surviving 30-40 years.
In conclusion: (1) Infra-diaphragmatic radiotherapy for
testicular cancer (median midplane dose 36Gy) leads to a
decrease of the renal function evaluated with radio-isotope
techniques in patients older than 40 years at the time of
treatment. If radiation is indicated in these patients, limited
fields and low doses should be considered. (2) Cisplatin-based
chemotherapy reduces the renal function subclinically during
the first 3-5 years post-treatment without recovery. Com-
bined treatment with chemotherapy and irradiation should be
avoided whenever possible as this furthermore increase the846 N. AASS et al.
renal impairment. (3) A longer follow-up (10-30 years) will
probably be necessary to assess the clinical significance ofthe
subclinical renal function impairment demonstrated by radio-
isotope techniques in patients undergoing modem treatment
for malignant germ cell tumours. Future studies should pre-
ferably include a control group of patients included in the
surveillance policy.
We are grateful to the staff at the Department of Nuclear Medicine
for skilful technical assistance. The study was financially supported
by The Norwegian Cancer Society.
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